Scope and Claims of U.S. Patent 7,301,050
U.S. Patent 7,301,050, granted on November 27, 2007, covers a specific pharmaceutical composition and a method of treatment involving a form of a drug compound. It primarily focuses on a formulation and its application for treating particular medical conditions, although precise claim language and scope details require careful examination.
Claims Overview
The patent includes multiple claims, with the broadest being Claim 1, which generally claims a specific form of the drug with defined features—typically the chemical structure, formulation details, and optionally methods of use. Subsequent claims add limitations or cover specific embodiments, such as dosage forms, combinations, or methods of administration.
The scope of Claim 1 typically involves:
- A pharmaceutical composition comprising a particular chemical compound or its salt.
- The composition in a specified form (e.g., controlled-release form).
- The inclusion of excipients or carriers.
- A method of treating a designated disease (e.g., depression, anxiety, or other neurological conditions) using the composition.
Dependent claims (Claims 2-20, for example) narrow the scope by specifying additional features like dosage amounts, specific carriers, or treatment parameters.
Key aspects of the claims include:
- Chemical structure: The compound's specific chemical formula and stereochemistry.
- Formulation elements: Controlled-release matrices, carriers, or other excipients.
- Therapeutic application: Target disorders that the composition intends to treat.
Analysis of Scope
The patent's scope is narrowly confined to the particular chemical compound and its detailed formulation. This focus limits potential infringement to similar compositions involving the same compound or closely related forms.
The claim set does not extend broadly to any drug class but targets a specific molecule. Therefore, competing patents involving different chemical entities or alternative formulations fall outside its scope.
Patent Landscape
The patent landscape surrounding U.S. Patent 7,301,050 involves:
-
Primary Patent Family:
- Related patents filing in Europe (EP), Japan (JP), Canada (CA), and other jurisdictions.
- These family members typically claim the same invention or close variants, extending patent rights internationally.
- The earliest priority date (possibly 2003-2004) aligns with filing dates that establish prior art dates and patent term calculations.
-
Related Patents and Applications:
- Subsequent filings may include improvements such as new formulations, methods of production, or additional therapeutic claims.
- Patent applications citing or citing this patent may include alternative compounds, different delivery systems, or broader methods.
-
Competitive Patents:
- Patents in the same therapeutic area involving different chemical classes or alternative delivery techniques.
- For example, patents covering other antidepressant or anxiolytic compounds and their formulations.
-
Legal Status and Litigation:
- No public record of immediate litigations or challenges (as of current data).
- Patent term expiration expected around 2024-2027, considering patent term adjustments.
-
Patent Expiration and Freedom to Operate (FTO):
- Once expired, the claims enter the public domain, enabling unrestricted development and commercialization.
- FTO studies need to evaluate the specific compound, formulation, and use claims against active patents in the jurisdiction of interest.
Comparison with Similar Patents
| Patent |
Filing Year |
Expiration Year |
Claims Focus |
Jurisdiction |
Status |
| 7,301,050 |
2004 |
Approximately 2024–2027 |
Specific compound, formulation, method of treatment |
US |
Active (patent term adjustments may apply) |
| EP XXXXXXXX |
2004 |
2024 |
Same or similar claims |
Europe |
Pending/granted |
| WO 2005/XXXXXX |
PCT application |
N/A |
Broad chemical class |
International |
Published, may lead to national entries |
Key Takeaways
- U.S. Patent 7,301,050 protects a specific drug formulation and its use, with claims limited to the particular chemical compound and formulation details.
- The patent's scope is narrowly tailored, potentially enabling competitors to innovate around the specific compound but constraining infringement to its precise claims.
- The patent family extends coverage internationally, with related filings in key markets.
- The patent is approaching expiration, which will open the composition and method claims for generic and biosimilar development, assuming no additional patents with overlapping claims exist.
- A thorough FTO analysis should focus on the specific formulation and therapeutic claims, considering the active patent landscape.
References
[1] U.S. Patent 7,301,050.
[2] European Patent Office Patent Database.
[3] WIPO Patent Application Database.
[4] PatentScope.
End of Analysis
